BENEFIT FROM ANTI-EGFR THERAPY IN KRAS, BRAF, NRAS, PI3KCA "ALL WILD TYPE", EGFR POSITIVE COLORECTAL CANCER PATIENTS.

被引：0
|
作者：
De Maglio, Giovanna [1 ]
Aprile, Giuseppe [2 ]
Foltran, Luisa [2 ]
Masiero, Elena [1 ]
Lutrino, Stefania [2 ]
Cardellino, Giovanni [2 ]
Fontanella, Caterina [2 ]
Fasola, Gianpiero [2 ]
Pizzolitto, Stefano [1 ]
机构：
[1] Univ Hosp, Dept Pathol, Udine, Italy
[2] Univ Hosp, Dept Oncol, Udine, Italy
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：v107 / v107
页数：1
相关论文
共 50 条
  • [31] Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status
    Pietrantonio, Filippo
    Maggi, Claudia
    Di Bartolomeo, Maria
    Facciorusso, Maria Grazia
    Perrone, Federica
    Testi, Adele
    Iacovelli, Roberto
    Miceli, Rosalba
    Bossi, Ilaria
    Leone, Giorgia
    Milione, Massimo
    Pelosi, Giuseppe
    de Braud, Filippo
    PLOS ONE, 2014, 9 (04):
  • [32] Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients
    Er, Tze-Kiong
    Chen, Chih-Chieh
    Bujanda, Luis
    Herreros-Villanueva, Marta
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [33] The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies
    Meriggi, Fausto
    Vermi, William
    Bertocchi, Paola
    Zaniboni, Alberto
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (01) : 8 - 12
  • [34] Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations
    Voutsadakis, Ioannis A.
    PHARMACOGENOMICS, 2025,
  • [35] EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer
    Algars, Annika
    Sundstrom, Jari
    Lintunen, Minnamaija
    Jokilehto, Terhi
    Kytola, Soili
    Kaare, Milja
    Vainionpaa, Reetta
    Orpana, Arto
    Osterlund, Pia
    Ristimaki, Ari
    Carpen, Olli
    Ristamaki, Raija
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (04) : 922 - 929
  • [36] KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
    Timar, J.
    Hegedus, B.
    Raso, E.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (08) : 813 - 823
  • [37] The secondary mutation of KRAS and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer
    Xia, X.
    Du, W.
    Zhu, Y.
    Bai, Y.
    Liu, M.
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (3-4) : 218 - 218
  • [38] Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in patients with metastatic colon cancer in wild-type KRAS patients
    Laurent-Puig, Pierre
    Cayre, Anne
    Manceau, Gilles
    Pezet, Denis
    Bachet, Jean-baptiste
    Thierry, Lecomte
    Bibeau, Frederic
    Boige, Valerie
    Bouche, Olivier
    Reid, Julia
    Stone, Steven
    Penault-Llorca, Fredrique
    CANCER RESEARCH, 2009, 69
  • [39] Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
    Morelli, M. Pia
    Overman, Michael J.
    Dasari, Arvind
    Kazmi, Syed Mohammad Ali
    Sanchez, Eduardo Vilar
    Eng, Cathy
    Kee, Bryan K.
    Deaton, Laurel
    Garrett, Chris R.
    Diehl, Frank
    Angenendt, Philipp
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice
    Vandemoortele, Thomas
    Nanni-Metellus, Isabelle
    Kaspi, Elise
    Secq, Veronique
    Laroumagne, Sophie
    Roll, Patrice
    Roca, Elisa
    Dutau, Herve
    Robaglia, Andree
    Astoul, Philippe
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
12345